| Code | CSB-RA1273MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ensituximab, targeting MUC5AC (Mucin 5AC), a high molecular weight glycoprotein that serves as a major gel-forming mucin in the respiratory and gastrointestinal tracts. MUC5AC plays a critical role in mucosal protection and barrier function under normal physiological conditions. However, aberrant expression of MUC5AC has been implicated in various pathological conditions, including chronic respiratory diseases, inflammatory bowel disease, and notably in several malignancies. MUC5AC is frequently overexpressed in pancreatic, gastric, ovarian, and lung adenocarcinomas, where it contributes to tumor progression, metastasis, and poor prognosis, making it an important biomarker and therapeutic target in oncology research.
Ensituximab is a chimeric (human-mouse) IgM anti-MUC5AC monoclonal antibody designed to eliminate MUC5AC-expressing tumor cells through immune effects such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This biosimilar antibody provides researchers with a valuable tool for investigating MUC5AC expression patterns, functional roles in disease pathogenesis, and potential therapeutic interventions. It supports studies in cancer biology, mucosal immunology, and epithelial cell research, enabling exploration of MUC5AC-mediated mechanisms in tumor microenvironments and inflammatory processes.
There are currently no reviews for this product.